Varian Medical Systems Reports Solid Growth in Net Earnings, Revenues, Net Orders, and Backlog for Fourth Quarter and Fiscal Year 2006 | Varian

Varian Medical Systems Reports Solid Growth in Net Earnings, Revenues, Net Orders, and Backlog for Fourth Quarter and Fiscal Year 2006

PALO ALTO, Calif., Oct. 25 /zh-hans/zh-hans/zh-hans/zh-hans/zh-hans/zh-hans/zh-hans/PRNewswire-FirstCall/zh-hans/zh-hans/zh-hans/zh-hans/zh-hans/zh-hans/zh-hans/ -- Varian Medical Systems (NYSE: VAR) today is reporting solid growth in net earnings, revenues, net orders, and backlog for the fourth quarter and full fiscal year 2006 with significant gains in its Oncology Systems and X-Ray Products businesses.

Compared to the same period last fiscal year, fourth-quarter revenues grew 18 percent to $454 million and net orders rose 12 percent to $545 million. Compared to fiscal year 2005 totals, annual revenues grew 16 percent to $1.6 billion, net orders rose 14 percent to $1.8 billion, and the year-ending backlog increased 19 percent to $1.4 billion.

For the fourth quarter, net earnings were $82 million or $0.62 per diluted share. Excluding $0.05 per diluted share of expense for stock options, a $0.07 per diluted share gain from discrete tax items, and a $0.01 per diluted share gain from discontinued operations, net earnings for the fourth quarter were $79 million or $0.59 per diluted share, up 31 percent from net earnings per diluted share in the year-ago period.

For fiscal year 2006, net earnings were $245 million or $1.81 per diluted share. Excluding $0.20 per diluted share of expenses for stock options, a $0.15 per diluted share gain from discrete tax items, and the $0.01 per diluted share gain from the discontinued operations, net earnings for the fiscal year were $251 million or $1.85 per diluted share, up 23 percent from net earnings per diluted share last fiscal year.

"Robust demand for advanced products for image-guided radiotherapy (IGRT), stereotactic radiosurgery, brachytherapy, and filmless X-ray imaging contributed to our growth in net orders, revenues, and net earnings during the quarter and the fiscal year," said Tim Guertin, president and CEO of Varian Medical Systems. "We ended fiscal year 2006 on a particularly strong note that sets the stage for continued growth in fiscal year 2007 and beyond."

"Excluding stock option expenses, fourth quarter operating earnings as a percentage of revenues improved by half a point to 24 percent, even with a quarter-over-quarter decline of half a point in the gross margin due to continued high ramp-up costs for our new On-Board Imager® (OBI) device for IGRT," Guertin said. "For the year, the company sustained operating earnings at 22 percent of revenues."

The company ended the year with $366 million in cash and marketable securities, and spent $72 million during the quarter to repurchase 1.5 million shares of common stock, leaving a balance of 1.5 million shares in its existing repurchase authorization.

Oncology Systems

Oncology Systems' fourth quarter revenues totaled $383 million, up 17 percent from the same period last fiscal year. Revenues for the fiscal year were $1.3 billion, up 16 percent from the fiscal year 2005 total.

Fourth-quarter net orders were $470 million, up 13 percent from the same period last year with 25 percent growth in North America and a 4 percent decline in international markets. Fiscal year net orders were $1.5 billion, up 13 percent from fiscal year 2005 totals with 19 percent growth in North America and 6 percent growth in international markets. "Respectable gains in Europe were partially offset by softness in Asia during the fiscal year," said Guertin.

"North American cancer treatment centers are again leading a major market transition toward IGRT and image-guided radiosurgery," Guertin said. "Our OBI devices together with our linear accelerators are being used more commonly to target smaller tumors more precisely. As of the end of the fourth quarter, we had more than 325 installations of our OBI devices complete or in progress. Our versatile top-of-the-line Trilogy accelerator for both radiotherapy and radiosurgery, as well as our brachytherapy and software products, contributed significantly to the growth in net orders and revenues for this business."

X-Ray Products

Fourth quarter revenues for the X-Ray Products business were $59 million, up 15 percent from the year-ago quarter, and revenues for the full fiscal year were $228 million, up 17 percent from fiscal year 2005. Compared to corresponding periods in fiscal year 2005, X-Ray Products' fourth quarter net orders rose 21 percent to $68 million and fiscal year net orders rose 19 percent to $242 million.

"X-Ray Products had another spectacular year of growth driven in large part by our rapidly expanding business in flat-panel digital detectors for filmless X-ray imaging," Guertin said. "Both net orders and shipments of our flat-panel detector devices were roughly double their totals from last fiscal year, and these products now make up about a fourth of the X-Ray Products business." During the quarter, this business completed construction of a new flat-panel production facility at its Salt Lake City manufacturing plant.

Other

The company's Other category, including the Security and Inspection Products business and the Ginzton Technology Center, recorded combined fourth quarter net orders of $7 million, down $8 million from an exceptionally high year-ago quarter. Net orders for fiscal year 2006 were $42 million, up 33 percent from totals for fiscal year 2005. Revenues for the quarter were $12 million, up $3 million from the year-ago period. Revenues for the fiscal year totaled $34 million, up 6 percent from the fiscal year 2005 total.

"Stronger demand for port security products, including strengthening demand in the U.S., contributed to the strong annual orders growth in this emerging business," Guertin said.

Outlook

"Excluding stock option expenses, we believe that total company revenues and earnings per diluted share for the first quarter of fiscal year 2007 should increase in the mid-teens above the comparable periods in fiscal 2006," Guertin said. "For the full fiscal year, we believe that revenues should increase by about 13 percent above fiscal year 2006 levels. We expect that earnings per diluted share excluding options expensing should be in the range of $2.08 to $2.10 for the full fiscal year 2007. Option expenses for fiscal year 2007 should be in the range of $0.21 to $0.24 per diluted share."

Investor Conference Call

Varian Medical Systems is scheduled to conduct its fiscal year 2006 conference call at 2 p.m. PT today. To hear a live webcast or replay of the call, visit the investor relations page on the company's web site at http:/zh-hans/zh-hans/zh-hans/zh-hans/zh-hans/zh-hans/zh-hans//zh-hans/zh-hans/zh-hans/zh-hans/zh-hans/zh-hans/zh-hans/www.varian.com/zh-hans/zh-hans/zh-hans/zh-hans/zh-hans/zh-hans/zh-hans/ where it will be archived for a year. To access the call via telephone, dial 1-800-299-8538 from inside the U.S. or 1-617-786-2902 from outside the U.S. and enter confirmation code 26183715. The replay can be accessed by dialing 1-888-286-8010 from inside the U.S. or 1-617-801-6888 from outside the U.S. and entering confirmation code 56460470. The telephone replay will be available through 5 p.m. PT, October 27, 2006. Additionally, certain non-GAAP information will be presented on the conference call. A reconciliation of such non-GAAP information to GAAP may be found on the investor relations page of the company's web site.

Varian Medical Systems, Inc. of Palo Alto, California is the world's leading manufacturer of medical products for treating cancer and other medical conditions with radiotherapy, brachytherapy, and radiosurgery. The company is also a premier supplier of X-ray tubes and digital detectors for imaging in medical, scientific, and industrial applications. Varian Medical Systems employs approximately 3,900 people who are located at manufacturing sites in North America and Europe and in its 56 sales and support offices around the world. Additional information is available on the company's investor relations web site at http:/zh-hans/zh-hans/zh-hans/zh-hans/zh-hans/zh-hans/zh-hans//zh-hans/zh-hans/zh-hans/zh-hans/zh-hans/zh-hans/zh-hans/www.varian.com/zh-hans/zh-hans/zh-hans/zh-hans/zh-hans/zh-hans/zh-hans/.

Note regarding reconciliation:

For comparison purposes, the company makes reference to certain net earnings and net earnings per diluted share results in the fourth quarter and full fiscal year that are not consistent with GAAP. These results were reached by excluding incremental non-cash share-based compensation expenses (which would have been consistent with GAAP if presented in prior years, but which are now inconsistent with GAAP due to changes in accounting standards), one-time tax benefits from the repatriation of foreign earnings under the Jobs Creation Act of 2004 and a deferred tax asset adjustment and an amount related to the release of a reserve for certain contingencies associated with the sale of its Electron Device Business in 1995. The company references those results to allow a better comparison of results in the current period to those in prior periods. The company's reference to these results should be considered in addition to results that are prepared under current accounting standards but should not be considered a substitute for results that are presented as consistent with GAAP.

Forward-Looking Statements

Except for historical information, this news release contains forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements concerning industry outlook, including market acceptance of or transition to new products or technology image-guided radiation therapy (IGRT), stereotactic radiosurgery, filmless X-rays, and security and inspection; growth drivers; the company's orders, revenues, backlog, or earnings growth; future financial results and any statements using the terms "should," "believe," "expect," or similar statements are forward- looking statements that involve risks and uncertainties that could cause the company's actual results to differ materially from those anticipated. Such risks and uncertainties include demand for the company's products; the company's ability to develop and commercialize new products; the company's ability to meet demand for manufacturing capacity; the company's reliance on sole or limited-source suppliers; the company's ability to maintain or increase operating margins; the impact of competitive products and pricing; the effect of economic conditions and currency exchange rates; the effect of changes in accounting principles; the company's ability to meet Food and Drug Administration and other regulatory requirements for product clearances or to comply with Food and Drug Administration and other regulatory regulations or procedures; the possibility that material product liability claims could harm future revenues or require the company to pay uninsured claims; the effect of environmental claims and expenses; the company's ability to protect the company's intellectual property; the impact of reduced or limited demand by sole purchasers of certain X-ray tubes; the impact of managed care initiatives, other health care reforms, and/zh-hans/zh-hans/zh-hans/zh-hans/zh-hans/zh-hans/zh-hans/or third-party reimbursement levels on capital expenditures for cancer care; the potential loss of key distributors or key personnel; consolidation in the X-ray tubes market; the ability to make strategic acquisitions and to successfully integrate the acquired operations into the company's business; the risk of operations interruptions due to terrorism, disease (such as Severe Acute Respiratory Syndrome and Avian Influenza) or other events beyond the company's control; and the other risks listed from time to time in the company's filings with the Securities and Exchange Commission, which by this reference are incorporated herein. The company assumes no obligation to update or revise the forward- looking statements in this release because of new information, future events, or otherwise.

A summary of earnings and other financial information follows.


              Varian Medical Systems, Inc. and Subsidiaries
              Condensed Consolidated Statements of Earnings
                               (Unaudited)

   (Dollars and shares in millions, except per share amounts)


                                 Q4 QTR     Q4 QTR      Q4 YTD     Q4 YTD
                                   2006       2005        2006       2005

  Net orders                     $545.1      488.3     1,819.5    1,591.0
   Oncology Systems               469.6      416.8     1,534.9    1,355.0
   X-Ray Products                  68.3       56.3       242.2      204.1
   Other                            7.2       15.2        42.4       31.9
  Order backlog                $1,400.6    1,179.0     1,400.6    1,179.0
  Revenues                       $454.0      386.2     1,597.8    1,382.6
   Oncology Systems               382.6      325.8     1,335.9    1,155.8
   X-Ray Products                  59.0       51.4       228.3      195.2
   Other                           12.4        9.0        33.6       31.6
  Cost of revenues (1)           $263.2      220.4       934.5      789.6
  Gross margin                    190.8      165.8       663.3      593.0
   As a percent of revenues       42.0%      42.9%       41.5%      42.9%
  Operating expenses
   Research and development (1)    27.7       21.6       100.4       82.1
   Selling, general and
    administrative (1)             65.7       54.4       253.5      205.9
  Operating earnings               97.4       89.8       309.4      305.0
   As a percent of revenues       21.4%      23.2%       19.4%      22.1%
  Interest income, net              2.5        1.1         9.3        3.3
  Earnings from continuing
   operations before taxes         99.9       90.9       318.7      308.3
  Taxes on earnings (1),(2)        19.0       29.9        75.1      101.7
  Earnings from continuing
   operations                      80.9       61.0       243.6      206.6
   As a percent of revenues       17.8%      15.8%       15.2%      14.9%
  Earnings from discontinued
   operations - net of taxes(3)     1.5         --         1.5         --
  Net earnings(1), (2)            $82.4       61.0       245.1      206.6
  Net earnings per share -
   basic: (1), (2)
   Continuing operations          $0.62       0.47        1.86       1.56
    Discontinued operations        0.01         --        0.01         --
    Net earnings per share        $0.63       0.47        1.87       1.56
  Net earnings per share -
   diluted: (1), (2)
   Continuing operations          $0.61       0.45        1.80       1.50
    Discontinued operations        0.01         --        0.01         --
    Net earnings per share        $0.62       0.45        1.81       1.50

  Shares used in the calculation
   of net earnings per share:
    Average shares outstanding -
     basic                        129.9      130.8       131.0      132.4
    Average shares outstanding -
     diluted                      134.0      136.0       135.4      137.8


  (1) Includes amounts for the incremental stock options and other share-
  based compensation expenses (referred to as "SFAS 123R") and its related
  tax benefits.

  (2) Includes a tax benefit related to the repatriation of foreign earnings
  and a deferred tax asset adjustment.

  (3) Amount represents the release of a reserve for certain contingencies
  associated with the sale of our Electron Device Business in 1995.

  (in millions, except per share amounts)


                                  Q4 QTR     Q4 QTR     Q4 YTD     Q4 YTD
                                   2006       2005       2006       2005
  Costs of revenues                $1.9         --        6.7         --
  Research & development            1.1         --        4.3         --
  Selling, general &
   administrative                   7.4         --       29.4         --
  Total SFAS 123R                  10.4         --       40.4         --
  Taxes on earnings
   SFAS 123R                       (3.5)        --      (13.8)        --
  Taxes on earnings -
   repatriation                    (1.8)        --      (12.0)        --
  Taxes on earnings -
   deferred tax asset
   adjustment                      (7.2)        --       (7.2)        --
  Earnings from discontinued
   operations - net of taxes       (1.5)        --       (1.5)        --
  Net earnings                    $(3.6)        --        5.9         --
  Net earnings per share -
   basic                         $(0.02)        --       0.05         --

  Net earnings per share -
   diluted                       $(0.03)        --       0.04         --


                 Varian Medical Systems, Inc. and Subsidiaries
                    Condensed Consolidated Balance Sheets

  (In thousands)

                                               September 29,  September 30,
                                                    2006           2005
                                                (Unaudited)
  Assets
    Current assets
    Cash and cash equivalents                     $272,508       $243,086
    Short-term marketable securities                93,599        135,356
    Accounts receivable, net                       471,820        351,899
    Inventories                                    189,653        164,873
    Deferred tax assets and other                  128,469        121,681
      Total current assets                       1,156,049      1,016,895

  Property, plant and equipment                    319,028        296,862
    Accumulated depreciation and amortization     (188,710)      (182,322)
      Net property, plant and equipment            130,318        114,540

  Long-term marketable securities                       --          3,679
  Goodwill                                         121,389        121,389
  Other assets                                     103,995         60,899
  Total assets                                  $1,511,751     $1,317,402

  Liabilities and Stockholders' Equity
  Current liabilities
    Accounts payable                               $77,985        $71,007
    Accrued expenses                               383,563        315,287
    Product warranty                                42,992         39,407
    Advance payments from customers                131,462        115,543
    Current maturities of long term debt             7,954          2,689
      Total current liabilities                    643,956        543,933
  Long-term accrued expenses and other              21,186         57,124
  Long-term debt                                    49,356         57,318
      Total liabilities                                           714,498
                                                   658,375

  Stockholders' Equity
  Common stock                                     129,721        130,715
  Capital in excess of par value                   265,214        150,466
  Retained earnings and accumulated other
   comprehensive loss                              402,318        377,846
      Total stockholders' equity                   797,253        659,027
  Total liabilities and stockholders' equity    $1,511,751     $1,317,402


   FOR INFORMATION CONTACT:
   Elisha Finney (650) 424-6803
   elisha.finney@varian.com

   Spencer Sias (650) 424-5782
   spencer.sias@varian.com

SOURCE: Varian Medical Systems, Inc.

CONTACT: Elisha Finney, +1-650-424-6803, or elisha.finney@varian.com, or
Spencer Sias, +1-650-424-5782, or
spencer.sias@varian.com

Web site: http:/zh-hans/zh-hans/zh-hans/zh-hans/zh-hans/zh-hans/zh-hans//zh-hans/zh-hans/zh-hans/zh-hans/zh-hans/zh-hans/zh-hans/www.varian.com/zh-hans/zh-hans/zh-hans/zh-hans/zh-hans/zh-hans/zh-hans/